AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18201433 — intervention group
Group type: COMPARATOR
Intervention: Control (Inhaled Fluticasone Propionate)
Number of subjects: 12
Study 15839852 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 80 microg kg(‐1) min(‐1)
Number of subjects: 12
Study 15839852 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 120 microg kg(‐1) min(‐1)
Number of subjects: 12
Study 15839852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15839852 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (both doses)
Number of subjects: 12
Study 12442019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunneled catheters
Number of subjects: 98
Study 12442019 — intervention group
Group type: COMPARATOR
Intervention: Nontunneled catheters
Number of subjects: 98
Study 9470002 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Thyroxine (8 micrograms/kg birthweight per day)
Number of subjects: 200
Study 9470002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 9470002 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Thyroxine
Number of subjects: 200
Study 7666874 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 849
Study 7666874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 849
Study 2505682 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU + PSK (3 g/day for 4 weeks and 5-FU 150 mg/day for 4 weeks, 10 courses)
Number of subjects: 262
Study 2505682 — intervention group
Group type: COMPARATOR
Intervention: 5-FU alone (for 4 weeks with alternate rest interval for 4 weeks)
Number of subjects: 262
Study 1187976 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (vodka mixed with a soft drink)
Number of subjects: 52
Study 1187976 — intervention group
Group type: COMPARATOR
Intervention: No alcohol (soft drink alone as placebo)
Number of subjects: 52
Study 31872771 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 31872771 — intervention group
Group type: COMPARATOR
Intervention: Routine Clinical Practice (RCP)
Number of subjects: 0
Study 29019167 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid simulation (breast jacket + SP)
Number of subjects: 82
Study 29019167 — intervention group
Group type: COMPARATOR
Intervention: Control (tabletop breast model)
Number of subjects: 82
Study 27793547 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (3 interactive workshops on cardiovascular disease prevention)
Number of subjects: 320
Study 27793547 — intervention group
Group type: COMPARATOR
Intervention: Control group (information by mail)
Number of subjects: 320
Study 26357419 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 L daily of EVIAN water on top of usual intake for 50 days
Number of subjects: 65
Study 26357419 — intervention group
Group type: COMPARATOR
Intervention: Usual lifestyle habits (Control)
Number of subjects: 65
Study 23531324 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 130/0.42
Number of subjects: 295
Study 23531324 — intervention group
Group type: COMPARATOR
Intervention: Ringer's acetate
Number of subjects: 295
Study 21256670 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/d
Number of subjects: 90
Study 21256670 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (twice a week for 4 weeks)
Number of subjects: 90
Study 21256670 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham-acupuncture, twice a week for 4 weeks)
Number of subjects: 90
Study 19765497 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioner (NP) lifestyle counseling with standardized computerized software program
Number of subjects: 457
Study 19765497 — intervention group
Group type: COMPARATOR
Intervention: General practitioner usual care (GP-UC)
Number of subjects: 457
Study 19765497 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioner (NP) lifestyle counseling
Number of subjects: 457
Study 17761230 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet (rich in fruits, vegetables, and low-fat dairy products) at intermediate sodium level (2,300 mg/day)
Number of subjects: 354
Study 17761230 — intervention group
Group type: COMPARATOR
Intervention: Control diet at intermediate sodium level (2,300 mg/day)
Number of subjects: 354
Study 17761230 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 354
Study 17761230 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 354
Study 15011426 — intervention group
Group type: EXPERIMENTAL
Intervention: Lockable CSE device (Group II)
Number of subjects: 60
Study 15011426 — intervention group
Group type: EXPERIMENTAL
Intervention: Lockable CSE device (Group III)
Number of subjects: 60
Study 15011426 — intervention group
Group type: COMPARATOR
Intervention: Conventional CSE device (Group I)
Number of subjects: 60
Study 15011426 — intervention group
Group type: EXPERIMENTAL
Intervention: Lockable CSE device (Group II and III)
Number of subjects: 60
Study 15669554 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (2 mg) and trimegestone (TMG 0.25 or 0.5 mg)
Number of subjects: 487
Study 15669554 — intervention group
Group type: COMPARATOR
Intervention: Estradiol and norethisterone acetate
Number of subjects: 487
Study 11506836 — intervention group
Group type: EXPERIMENTAL
Intervention: OC-fluconazole
Number of subjects: 26
Study 11506836 — intervention group
Group type: COMPARATOR
Intervention: OC-placebo
Number of subjects: 26
Study 9242038 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (100,000 IU)
Number of subjects: 394
Study 9242038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 394
Study 8294170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 2.5% gel applied twice a day for seven days (250 mg per day)
Number of subjects: 56
Study 8294170 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 56
Study 8294170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 2.5% gel
Number of subjects: 56
Study 3327724 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (1.5 mg/kg)
Number of subjects: 110
Study 3327724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 3327724 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Aminophylline and Placebo)
Number of subjects: 110
Study 29402711 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin alone: 0.2 mg/d
Number of subjects: 310
Study 29402711 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2 mg/d plus celecoxib: 200 mg/d
Number of subjects: 310
Study 27281374 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Attention Control Training Program (Drug‐ACTP)
Number of subjects: 48
Study 27281374 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 48
Study 25428341 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Huoxue Granule (BHG)
Number of subjects: 62
Study 25428341 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine hydrochloride dispersible tablet (Control)
Number of subjects: 62
Study 23713299 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct moxibustion at Sihua points (Geshu (BL 17) and Danshu (BL 19)), three moxa-cones once a day for ten days
Number of subjects: 80
Study 23713299 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (Navelbine and cisplatin)
Number of subjects: 80
Study 20626953 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive consent
Number of subjects: 185
Study 20626953 — intervention group
Group type: COMPARATOR
Intervention: Active consent
Number of subjects: 185
Study 18378749 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for stress urinary incontinence
Number of subjects: 655
Study 16600816 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) supplementation at doses of 1.35, 2.7, or 4.05 g/d for 12 weeks
Number of subjects: 0
Study 16600816 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) supplementation
Number of subjects: 0
Study 16600816 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no additional omega‐3 polyunsaturated fatty acids)
Number of subjects: 0
Study 12560440 — intervention group
Group type: EXPERIMENTAL
Intervention: RT‐PCR positive for PSA
Number of subjects: 162
Study 12560440 — intervention group
Group type: COMPARATOR
Intervention: RT‐PCR negative for PSA
Number of subjects: 162
Study 10867111 — intervention group
Group type: EXPERIMENTAL
Intervention: R121919 (5-40 mg)
Number of subjects: 24
Study 10867111 — intervention group
Group type: EXPERIMENTAL
Intervention: R121919 (40-80 mg)
Number of subjects: 24
Study 10867111 — intervention group
Group type: EXPERIMENTAL
Intervention: R121919 (overall)
Number of subjects: 24
Study 9263770 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP*A gene frequency
Number of subjects: 140
Study 9263770 — intervention group
Group type: EXPERIMENTAL
Intervention: PGM1*2 gene frequency
Number of subjects: 140
Study 9263770 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ACP with other populations
Number of subjects: 140
Study 9263770 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PGM1 with other populations
Number of subjects: 140
Study 1297878 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physical trainings without coronary active agents
Number of subjects: 51
Study 1297878 — intervention group
Group type: COMPARATOR
Intervention: Physical exercises with antianginal drugs (first control group)
Number of subjects: 51
Study 1297878 — intervention group
Group type: COMPARATOR
Intervention: Therapeutical exercises, graded walking, nitrates, beta-blockers, calcium antagonists (second control group)
Number of subjects: 51
Study 6381170 — intervention group
Group type: EXPERIMENTAL
Intervention: Theocontin Continus tablets
Number of subjects: 25
Study 6381170 — intervention group
Group type: COMPARATOR
Intervention: Nuelin S.A.
Number of subjects: 25
Study 30368939 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 IU/kg VE
Number of subjects: 216
Study 30368939 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU/kg VE
Number of subjects: 216
Study 30368939 — intervention group
Group type: COMPARATOR
Intervention: 0 IU/kg VE
Number of subjects: 216
Study 30368939 — intervention group
Group type: COMPARATOR
Intervention: Ageing corn diet
Number of subjects: 216
Study 28646416 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (solifenacin 5 mg plus mirabegron 25 mg for the first 4 weeks/50 mg for the last 8 weeks)
Number of subjects: 2054
Study 28646416 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin 5 mg
Number of subjects: 2054
Study 28646416 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin 10 mg
Number of subjects: 2054
Study 25885649 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective physical activity (assessed via the International Physical Activity Questionnaire; IPAQ)
Number of subjects: 68
Study 25885649 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective physical activity (accelerometry; GT3X)
Number of subjects: 68
Study 25885649 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective moderate PA (IPAQ)
Number of subjects: 68
Study 25885649 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective MVPA (IPAQ)
Number of subjects: 68
Study 25885649 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time (ST)
Number of subjects: 68
Study 23598181 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (brief counselling from trained family doctors)
Number of subjects: 272
Study 23598181 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 272
Study 21494790 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (400 mg)
Number of subjects: 30
Study 21494790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19726226 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin (3800 IU anti-Xa once a day)
Number of subjects: 1150
Study 19726226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1150
Study 17803380 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser followed by ultrasonic scaling (DL + US)
Number of subjects: 22
Study 17803380 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic scaling alone (US)
Number of subjects: 22
Study 15084619 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sequential chemotherapy and autografting
Number of subjects: 70
Study 12404273 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 299
Study 12404273 — intervention group
Group type: COMPARATOR
Intervention: No estrogen replacement therapy (No ERT)
Number of subjects: 299
Study 9633494 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular technique (TPEG)
Number of subjects: 37
Study 9633494 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 37
Study 9633494 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study 7823359 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive surveillance (n = 56)
Number of subjects: 156
Study 7823359 — intervention group
Group type: COMPARATOR
Intervention: Routine surveillance (n = 50)
Number of subjects: 156
Study 7823359 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive surveillance (n = 23)
Number of subjects: 156
Study 7823359 — intervention group
Group type: COMPARATOR
Intervention: Routine surveillance (n = 20)
Number of subjects: 156
Study 2195575 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol-induced panic attacks (panicking patients)
Number of subjects: 115
Study 350590 — intervention group
Group type: COMPARATOR
Intervention: β‐acetyl digoxin (D) 0.1, 0.2, 0.3, 0.4, 0.5 or 0.6 mg daily for 7 days
Number of subjects: 120
Study 350590 — intervention group
Group type: EXPERIMENTAL
Intervention: digitoxin (Dt) 0.04, 0.08, 0.12, or 0.16 mg daily for 7 days
Number of subjects: 120
Study 7051985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 223
Study 7051985 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 223
Study 30676487 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 900mg oral dose of delafloxacin
Number of subjects: 460
Study 30676487 — intervention group
Group type: COMPARATOR
Intervention: Single 250mg intramuscular ceftriaxone
Number of subjects: 460
Study 28952914 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.25 mg/kg, max 25 mg)
Number of subjects: 0
Study 28952914 — intervention group
Group type: COMPARATOR
Intervention: Alteplase (0.9 mg/kg, max 90 mg)
Number of subjects: 0
Study 26674122 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Vitality Training (CVT)
Number of subjects: 74
Study 26674122 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised cognitive training (CCT)
Number of subjects: 74
Study 26674122 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised cognitive training (CCT) and Cognitive Vitality Training (CVT)
Number of subjects: 74
Study 26674122 — intervention group
Group type: COMPARATOR
Intervention: Active Control Group (ACG)
Number of subjects: 74
Study 25172875 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized insulin infusion program (CIIP)
Number of subjects: 210
Study 22775976 — intervention group
Group type: COMPARATOR
Intervention: AZD1656 (7, 20, 40 or 80 mg) twice daily for 8 days
Number of subjects: 52
Study 22775976 — intervention group
Group type: COMPARATOR
Intervention: AZD1656 (15-45 mg) twice daily for 28 days
Number of subjects: 52
Study 22775976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 21057411 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated long-term program of management at FEC
Number of subjects: 114
Study 21057411 — intervention group
Group type: COMPARATOR
Intervention: Routine psychiatric services (control group)
Number of subjects: 114
Study 17875625 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 11
Study 17875625 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstructured support
Number of subjects: 11
Study 15381116 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE1 polymorphism in hypoxemic group
Number of subjects: 44
Study 15381116 — intervention group
Group type: COMPARATOR
Intervention: ACE1 polymorphism in SARS cases
Number of subjects: 44
Study 11380778 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold alloy crowns cemented with zinc phosphate cement
Number of subjects: 40
Study 11380778 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold alloy crowns with manual burnishing technique
Number of subjects: 40
Study 11380778 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure titanium crowns cemented with zinc phosphate cement
Number of subjects: 40
Study 11380778 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure titanium crowns with manual burnishing technique
Number of subjects: 40
Study 9121993 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic active can (AC) (model 7219C system, Medtronic, Inc.)
Number of subjects: 304
Study 9121993 — intervention group
Group type: COMPARATOR
Intervention: Passive can (PC) (model 7219D system)
Number of subjects: 304
Study 9121993 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 304
Study 8506191 — intervention group
Group type: EXPERIMENTAL
Intervention: nisoldipine 10 mg twice a day for 8 weeks
Number of subjects: 28
Study 8506191 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine 20 mg twice a day for 8 weeks
Number of subjects: 28
Study 8506191 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study 8506191 — intervention group
Group type: EXPERIMENTAL
Intervention: nisoldipine
Number of subjects: 28
Study 8506191 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine
Number of subjects: 28
Study 8506191 — intervention group
Group type: EXPERIMENTAL
Intervention: nisoldipine and nifedipine
Number of subjects: 28
Study 2965139 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol procaterol hydrochloride at 5 micrograms per puff
Number of subjects: 10
Study 2965139 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral procaterol hydrochloride at 25 micrograms
Number of subjects: 10
Study 2965139 — intervention group
Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 10
Study 28211031 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher proportion of female peers in the classroom
Number of subjects: 0
Study 28211031 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-achieving classroom
Number of subjects: 0
Study 28211031 — intervention group
Group type: COMPARATOR
Intervention: Average classroom achievement
Number of subjects: 0
Study 27145977 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal naloxone (2 to 8 mg) delivered in low volumes (0.1 to 0.2 mL) using an Aptar Unit‐Dose device
Number of subjects: 0
Study 27145977 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular naloxone (0.4 mg)
Number of subjects: 0
Study 27145977 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal naloxone (4 mg) delivered in a single device (0.1 mL)
Number of subjects: 0
Study 24675370 — intervention group
Group type: EXPERIMENTAL
Intervention: IA injection of 30IU of BoNT A
Number of subjects: 36
Study 24675370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 22617279 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg per day of lactotripeptides for 3 months
Number of subjects: 89
Study 22617279 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg per day of lactotripeptides for 3 months
Number of subjects: 89
Study 22617279 — intervention group
Group type: COMPARATOR
Intervention: Placebo milk drink without lactotripeptides
Number of subjects: 89
Study 19117242 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle sampling with suction
Number of subjects: 52
Study 19117242 — intervention group
Group type: COMPARATOR
Intervention: EUS-guided fine-needle sampling without suction
Number of subjects: 52
Study 17162048 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-Free Vaginal Tape
Number of subjects: 120
Study 17162048 — intervention group
Group type: COMPARATOR
Intervention: Transobturator Vaginal Tape Inside-Out
Number of subjects: 120
Study 16381203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical disc arthroplasty
Number of subjects: 46
Study 16381203 — intervention group
Group type: COMPARATOR
Intervention: Cervical fusion
Number of subjects: 46
Study 11593943 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality salience induction
Number of subjects: 240
Study 11593943 — intervention group
Group type: COMPARATOR
Intervention: Control induction
Number of subjects: 240
Study 9722212 — intervention group
Group type: EXPERIMENTAL
Intervention: University of Wisconsin solution (UW group)
Number of subjects: 21
Study 9722212 — intervention group
Group type: COMPARATOR
Intervention: Bretschneider's Histidine‐Tryptophan‐Ketoglutarate solution (HTK group)
Number of subjects: 21
Study 8067218 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural bupivacaine/morphine for 48 h postoperatively plus oral piroxicam
Number of subjects: 42
Study 8067218 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia followed by a conventional intramuscular opioid and acetaminophen regimen
Number of subjects: 42
Study 3044474 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir treatment
Number of subjects: 22
Study 3044474 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 22
Study 31362882 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized Ketamine 1mg.kg‐1 (Group K‐N1)
Number of subjects: 100
Study 31362882 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized Ketamine 2mg.kg‐1 (Group K‐N2)
Number of subjects: 100
Study 31362882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Ketamine 0.5mg.kg‐1 (Group K‐IV)
Number of subjects: 100
Study 31362882 — intervention group
Group type: COMPARATOR
Intervention: Saline Placebo (Group C)
Number of subjects: 100
Study 31362882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and Nebulized Ketamine Groups
Number of subjects: 100
Study 28062595 — intervention group
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11 PET/CT at 3 h after injection
Number of subjects: 112
Study 28062595 — intervention group
Group type: COMPARATOR
Intervention: 68Ga-PSMA-11 PET/CT at 1 h after injection
Number of subjects: 112